Treatment after JAK Inhibitor in Patients with Rheumatoid Arthritis – What to do Next?

Is it advisable to switch from one JAK inhibitor (JAKi) to another in patients with rheumatoid arthritis (RA)? What is the effectiveness of cycling JAKi of different classes compared with switching to a biological disease-modifying antirheumatic drug (bDMARD) in patients with RA after failure to the first JAKi?